Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Conditions
Interventions
Nerinetide (NA-1), 2.6 mg/kg
Placebo
Locations
50
United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
California Pacific Medical Center - Davies Campus
San Francisco, California, United States
Providence Little Company of Mary Medical Center Torrance
Torrance, California, United States
Swedish Medical Center
Englewood, Colorado, United States
Yale New Haven Hospital
New Haven, Connecticut, United States
Baptist Health Medical Center
Jacksonville, Florida, United States
Start Date
March 1, 2017
Primary Completion Date
November 20, 2019
Completion Date
November 20, 2019
Last Updated
October 10, 2022
NCT06658197
NCT02879123
NCT05338697
NCT06075628
NCT06094478
NCT06157502
Lead Sponsor
NoNO Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions